GCTx launches with bold cell therapy claim

GC Therapeutics (GCTx) has launched with the promise to scale and unlock the next generation of cell therapy.

GCTx’s induced pluripotent stem cell (iPSC) programming platform, TFome (transcription-factor-ome), was invented and developed by a team of scientists in the lab of George Church at Harvard Medical School and the Wyss Institute.

This platform integrates the latest advancements in synthetic biology, gene editing, cell engineering and machine learning to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of disease areas.